Diflucortolone valerate is a potent synthetic topical corticosteroid widely used in dermatological practice for its strong anti-inflammatory, anti-allergic, and anti-pruritic properties. Classified as a “potent” (Class 3) corticosteroid in the New Zealand topical steroid system, it is approximately 100-150 times more potent than hydrocortisone, making it an effective treatment for various inflammatory skin conditions.
This review provides comprehensive information about this important pharmaceutical ingredient, exploring its chemical properties, clinical applications, mechanism of action, and safety profile.
Introduction
Diflucortolone valerate was introduced in Germany more than a decade ago and subsequently became available in several Asian countries. It is commonly marketed under the brand name Nerisone (or Nerisona), available in formulations of 0.1% and 0.3% concentrations in various bases including cream, ointment, and fatty ointment.
As a corticosteroid esterified with valeric acid, diflucortolone valerate demonstrates enhanced lipophilicity, which facilitates its penetration into the skin while maintaining potent anti-inflammatory activity. Its effectiveness, combined with a relatively favorable safety profile when used appropriately, has made it a valuable therapeutic tool in dermatological practice worldwide.
Chemical Structure and Properties
Diflucortolone valerate has the chemical formula C27H36F2O5 and a molecular weight of 478.57 g/mol. Structurally, it is characterized as a 9α-fluoro derivative of fluocortolone with an additional fluorine atom and esterification with valeric acid. It appears as a white to creamy white crystalline powder with a melting point of approximately 220°C.
The compound has specific solubility characteristics that influence its pharmaceutical formulation: it is practically insoluble in water, freely soluble in dichloromethane and dioxan, sparingly soluble in ether, and slightly soluble in methanol. Its chemical structure can be represented by the IUPAC name 2-[(1S,2R,3aS,3bS,5S,9aS,9bR,10S,11aS)-5,9b-difluoro-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl pentanoate.
DFV-Based Medicines
Diflucortolone valerate is available in various formulations worldwide. Here are eight prominent medications containing this active ingredient:
- Nerisone/Nerisona – Available as cream, ointment, and fatty ointment in 0.1% and 0.3% concentrations
- Nerisone Forte – Higher potency formulation with 0.3% concentration
- Neriderm – Ointment formulation available in some markets
- Travocort – Combination product containing 0.1% diflucortolone valerate and 1% isoconazole nitrate for treatment of inflammatory or eczematised dermatomycosis
- Divicon – Manufactured by Valor Pharmaceuticals
- Pevaderm-D – Manufactured by Safe Pharmaceutical (PVT) Ltd
- Valsozol – Manufactured by Tabros Pharma
- Temetex/Afusona/Texmeten – Alternative brand names in different regions
Mechanism of Action
Diflucortolone valerate exerts its therapeutic effects through multiple pathways that collectively result in potent anti-inflammatory activity. Upon topical application, both the intact ester (diflucortolone valerate) and the free diflucortolone arising from cleavage of the ester are pharmacologically active.
The primary mechanism involves the induction of lipocortins, which are phospholipase A2 inhibitory proteins. By inhibiting phospholipase A2, diflucortolone valerate prevents the release of arachidonic acid from cell membrane phospholipids. This inhibition subsequently blocks the formation, release, and activity of endogenous chemical inflammatory mediators such as prostaglandins and leukotrienes.
Additionally, diflucortolone valerate works through a process called transrepression. After binding to the glucocorticoid receptor in the cytoplasm, the drug-receptor complex migrates to the nucleus where it produces two significant effects: stimulation of transcription of anti-inflammatory genes (including tyrosine aminotransferase, phosphoenolpyruvate carboxykinase, and IL-10) and suppression of expression of proinflammatory genes responsible for producing cytokines, growth factors, and adhesion molecules. This dual molecular action contributes to the compound’s effective control of inflammatory skin conditions.
Pharmacokinetics
The pharmacokinetic profile of diflucortolone valerate is characterized by limited systemic absorption, rapid metabolism, and elimination primarily through urine and feces. When applied topically, the percutaneous absorption of diflucortolone valerate is relatively low, with less than 1% of the topically applied dose being absorbed through the skin within four hours of application.
After entering the systemic circulation, diflucortolone valerate is rapidly hydrolyzed to diflucortolone and the corresponding fatty acid within minutes. The liver metabolizes diflucortolone quickly, with analyses showing 11-keto-diflucortolone as the major metabolite in plasma.
The elimination half-life of diflucortolone is approximately 4-5 hours, while the half-life of diflucortolone valerate is around 9 hours. The compound and its metabolites are eliminated from the body in a ratio of 75:25 through urine and feces, respectively.
In vasoconstriction tests on human skin with experimentally induced hyperemia, a water/oil emulsion containing just 0.001% diflucortolone valerate demonstrated equivalent efficacy to a similar preparation containing 0.1% fluocortolone, highlighting its potency.
Therapeutic Uses
Diflucortolone valerate is indicated for various dermatological conditions that respond to corticosteroid therapy. The following table outlines its primary therapeutic applications:
| Condition | Formulation | Treatment Duration | Evidence |
|---|---|---|---|
| Corticosteroid-responsive acute skin diseases | 0.1% cream, ointment, fatty ointment | Maximum 4 weeks | Strong efficacy with rapid onset of effect demonstrated in multicenter trials |
| Corticosteroid-responsive chronic skin diseases | 0.1% cream, ointment, fatty ointment | Maximum 4 weeks | Proven efficacy in Southeast Asian multicentre trials involving 897 patients |
| Severe chronic recurrent and resistant skin diseases | 0.3% cream/ointment (Nerisone Forte) | Limited duration | Pronounced efficacy with low incidence of side effects in Philippines trial with 143 patients |
| Inflammatory or eczematised dermatomycosis | Combination with antimicrobials (e.g., Travocort – with isoconazole nitrate) | Variable | Superior efficacy compared to plain antifungal in randomized double-blind study of 294 patients in Thailand |
| Bacterial or mycotically infected skin diseases | Combination with chlorquinaldol | Variable | Better efficacy than combination containing betamethasone 17-valerate, gentamicin, tolnaftate and clioquinol in double-blind trial |
Side Effects
While diflucortolone valerate is generally well-tolerated when used as directed, it may cause various adverse effects, particularly with prolonged use, application to large surface areas, or application under occlusive dressings. The most common side effects include:
Local skin reactions are the most frequently observed adverse effects. These include skin irritation, vesicles, or red patches on the skin at the application site. These reactions are generally mild and resolve upon discontinuation of treatment.
More serious adverse effects can occur with prolonged use or systemic absorption, reflecting typical corticosteroid side effects. Animal studies demonstrated that following daily application of diflucortolone valerate oily cream to shaved and scarified skin of dogs over 13-14 weeks, systemic corticoid effects occurred only after application of amounts exceeding 100 mg/kg.
In experimental studies, typical corticosteroid effects such as thymolysis (atrophy of the thymus) and atrophy of the adrenal cortex were observed at high doses. However, these effects are unlikely to occur with normal therapeutic use for limited duration.
Drug Interactions
Although topical corticosteroids like diflucortolone valerate have limited systemic absorption, potential drug interactions may occur, particularly with increased absorption or when used on large areas of the body. The search results indicate several potential interactions with various medications.
Some notable interaction categories include:
Drugs that may increase the serum level of diflucortolone include abacavir and abametapir, which may decrease the excretion rate or increase the concentration of diflucortolone.
The risk or severity of adverse effects can be increased when diflucortolone is combined with immunosuppressants like abatacept.
Diflucortolone may increase the metabolism of certain drugs such as abemaciclib and acalabrutinib.
As with all medications, healthcare providers should be consulted about potential drug interactions, especially for patients on multiple medications or with complex medical conditions.
Safety Considerations
Several important safety considerations should be taken into account when prescribing or using diflucortolone valerate:
Diflucortolone valerate is contraindicated in patients with hypersensitivity to the drug, any of its ingredients, or other corticosteroids. It should not be used in skin diseases in infants under one year of age.
The safety and effectiveness of diflucortolone valerate have not been established in pediatric patients less than 18 years of age or in geriatric patients over 65 years of age, indicating a need for cautious use in these populations.
Teratology studies have raised concerns about embryotoxic and teratogenic effects. Animal studies showed that dermal application of diflucortolone valerate ointment to scarified skin during pregnancy organogenesis produced typical steroidal teratogenic effects at high doses (exceeding 500 mg/kg/day of 0.1% ointment in rats and 50 mg/kg/day in rabbits). Effects included delayed ossification, umbilical hernia, caudal aplasia, reduced fetal weights, increased perinatal mortality, cleft palate, and shortened limbs.
The maximum recommended duration of treatment is 4 weeks, as prolonged use increases the risk of adverse effects.
Regulatory Status
Diflucortolone valerate has received regulatory approvals in multiple countries worldwide, though the search results provide limited specific information about its current regulatory status across different jurisdictions.
The compound was introduced in Germany and subsequently in Asian countries more than a decade ago. It was submitted to the FDA in July 1984 by Schering AG, though the current FDA approval status isn’t explicitly mentioned in the search results.
In Canada, product monographs indicate that NERISONE® (diflucortolone valerate) preparations are distributed by GlaxoSmithKline Inc., suggesting regulatory approval in that country.
The medication appears to be marketed under various brand names in different countries, including Pakistan, Thailand, Philippines, and Indonesia, indicating widespread regulatory acceptance.
Conclusion
Diflucortolone valerate represents an important therapeutic option in dermatological practice. As a potent topical corticosteroid, it provides effective relief for patients suffering from various inflammatory and allergic skin conditions. Its chemical structure, with fluorination and esterification with valeric acid, contributes to its enhanced potency and skin penetration properties.
The pharmacokinetic profile of diflucortolone valerate, characterized by limited systemic absorption and relatively rapid metabolism and elimination, contributes to its favorable safety profile when used as directed. However, like all corticosteroids, it carries risks of both local and systemic adverse effects, particularly with prolonged use or application to large body areas.
Healthcare providers should carefully consider the benefit-risk profile for each patient, paying particular attention to contraindications, appropriate duration of therapy, and special populations such as pediatric and geriatric patients. When used appropriately, diflucortolone valerate remains a valuable tool in the management of corticosteroid-responsive dermatological conditions.
